{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:38:05Z","timestamp":1791898685329,"version":"4.3.4"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,11,7]],"date-time":"2006-11-07T00:00:00Z","timestamp":1162857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,11,7]],"date-time":"2006-11-07T00:00:00Z","timestamp":1162857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hum Genet"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1007\/s00439-006-0280-4","type":"journal-article","created":{"date-parts":[[2006,11,6]],"date-time":"2006-11-06T14:38:08Z","timestamp":1162823888000},"page":"1-22","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":155,"title":["New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy"],"prefix":"10.1007","volume":"121","author":[{"given":"Michael","family":"Beck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,11,7]]},"reference":[{"key":"280_CR1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1067\/mpd.2001.112171","volume":"138","author":"G Altarescu","year":"2001","unstructured":"Altarescu G, Hill S, Wiggs E, Jeffries N, Kreps C, Parker CC, Brady RO, Barton NW, Schiffmann R (2001) The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher\u2019s disease. J Pediatr 138:539\u2013547","journal-title":"J Pediatr"},{"key":"280_CR2","first-page":"132","volume":"3","author":"A Amalfitano","year":"2001","unstructured":"Amalfitano A, Bengur AR, Morse RP, Majure JM, Case LE, Veerling DL, Mackey J, Kishnani P, Smith W, McVie-Wylie A, Sullivan JA, Hoganson GE, Phillips JA III, Schaefer GB, Charrow J, Ware RE, Bossen EH, Chen YT (2001) Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial. Genet Med 3:132\u2013138","journal-title":"Genet Med"},{"key":"280_CR3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ymgme.2005.03.010","volume":"85","author":"Y An","year":"2005","unstructured":"An Y, Young SP, Kishnani PS, Millington DS, Amalfitano A, Corz D, Chen YT (2005) Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease. Mol Genet Metab 85:247\u2013254","journal-title":"Mol Genet Metab"},{"key":"280_CR4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/01.GIM.0000153660.88672.3C","volume":"7","author":"HC Andersson","year":"2005","unstructured":"Andersson HC, Charrow J, Kaplan P, Mistry P, Pastores GM, Prakash-Cheng A, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ (2005) Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet Med 7:105\u2013110","journal-title":"Genet Med"},{"key":"280_CR5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s004310000630","volume":"160","author":"M Aoki","year":"2001","unstructured":"Aoki M, Takahashi Y, Miwa Y, Iida S, Sukegawa K, Horai T, Orii T, Kondo N (2001) Improvement of neurological symptoms by enzyme replacement therapy for Gaucher disease type IIIb. Eur J Pediatr 160:63\u201364","journal-title":"Eur J Pediatr"},{"key":"280_CR6","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/(SICI)1099-0496(199804)25:4<278::AID-PPUL8>3.0.CO;2-G","volume":"25","author":"IM Balfour-Lynn","year":"1998","unstructured":"Balfour-Lynn IM, Prasad SA, Laverty A, Whitehead BF, Dinwiddie R (1998) A step in the right direction: assessing exercise tolerance in cystic fibrosis. Pediatr Pulmonol 25:278\u2013284","journal-title":"Pediatr Pulmonol"},{"key":"280_CR7","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","volume":"324","author":"NW Barton","year":"1991","unstructured":"Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE et al (1991) Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease. N Engl J Med 324:1464\u20131470","journal-title":"N Engl J Med"},{"key":"280_CR8","first-page":"9","volume":"3","author":"M Beck","year":"2006","unstructured":"Beck M (2006) Galsulfase: enzyme-replacement therapy for mucopolysaccharidosis Type VI (Maroteaux\u2013Lamy syndrome). Therapy 3:9\u201317","journal-title":"Therapy"},{"key":"280_CR9","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2362.2004.01424.x","volume":"34","author":"M Beck","year":"2004","unstructured":"Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, Linhart A, Sunder-Plassmann G, Houge G, Ramaswami U, Gal A, Mehta A (2004) Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 34:838\u2013844","journal-title":"Eur J Clin Invest"},{"issue":"Suppl 1","key":"280_CR10","first-page":"67","volume":"13","author":"M Beck","year":"2005","unstructured":"Beck M, Harmatz P, Giugliani R, Schwartz I, Guffon N, Sa Miranda MC, Teles EL, Wraith JE, Scarpa M, Berger KI, Swiedler SJ (2005) Follow-up extension study of a double-blind phase 3 clinical study of recombinant human Arylsulfatase B (rhASB) in patients with Mucopolysaccharidosis VI (MPS VI) (abstract). Eur J Hum Genet 13(Suppl 1):67","journal-title":"Eur J Hum Genet"},{"key":"280_CR11","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/01.wnl.0000194225.78917.de","volume":"66","author":"B Bembi","year":"2006","unstructured":"Bembi B, Marchetti F, Guerci VI, Ciana G, Addobbati R, Grasso D, Barone R, Cariati R, Fernandez-Guillen L, Butters T, Pittis MG (2006) Substrate reduction therapy in the infantile form of Tay\u2013Sachs disease. Neurology 66:278\u2013280","journal-title":"Neurology"},{"key":"280_CR12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.tem.2004.05.003","volume":"15","author":"V Bernier","year":"2004","unstructured":"Bernier V, Lagace M, Bichet DG, Bouvier M (2004) Pharmacological chaperones: potential treatment for conformational diseases. Trends Endocrinol Metab 15:222\u2013228","journal-title":"Trends Endocrinol Metab"},{"key":"280_CR13","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1172\/JCI200419205","volume":"113","author":"A Biffi","year":"2004","unstructured":"Biffi A, De Palma M, Quattrini A, Del Carro U, Amadio S, Visigalli I, Sessa M, Fasano S, Brambilla R, Marchesini S, Bordignon C, Naldini L (2004) Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. J Clin Invest 113:1118\u20131129","journal-title":"J Clin Invest"},{"key":"280_CR14","doi-asserted-by":"crossref","first-page":"25680","DOI":"10.1074\/jbc.273.40.25680","volume":"273","author":"RG Boot","year":"1998","unstructured":"Boot RG, Renkema GH, Verhoek M, Strijland A, Bliek J, de Meulemeester TM, Mannens MM, Aerts JM (1998) The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem 273:25680\u201325685","journal-title":"J Biol Chem"},{"key":"280_CR15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2003-05-1612","volume":"103","author":"RG Boot","year":"2004","unstructured":"Boot RG, Verhoek M, de Fost M, Hollak CE, Maas M, Bleijlevens B, van Breemen MJ, van Meurs M, Boven LA, Laman JD, Moran MT, Cox TM, Aerts JM (2004) Marked elevation of the chemokine CCL18\/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 103:33\u201339","journal-title":"Blood"},{"key":"280_CR16","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/rcm.728","volume":"16","author":"F Boscaro","year":"2002","unstructured":"Boscaro F, Pieraccini G, la Marca G, Bartolucci G, Luceri C, Luceri F, Moneti G (2002) Rapid quantitation of globotriaosylceramide in human plasma and urine: a potential application for monitoring enzyme replacement therapy in Anderson\u2013Fabry disease. Rapid Commun Mass Spectrom 16:1507\u20131514","journal-title":"Rapid Commun Mass Spectrom"},{"key":"280_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM197307052890103","volume":"289","author":"RO Brady","year":"1973","unstructured":"Brady RO, Tallman JF, Johnson WG, Gal AE, Leahy WR, Quirk JM, Dekaban AS (1973) Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry\u2019s disease. N Engl J Med 289:9\u201314","journal-title":"N Engl J Med"},{"key":"280_CR18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10545-005-4416-9","volume":"28","author":"J Brinkman","year":"2005","unstructured":"Brinkman J, Wijburg FA, Hollak CE, Groener JE, Verhoek M, Scheij S, Aten J, Boot RG, Aerts JM (2005) Plasma chitotriosidase and CCL18: early biochemical surrogate markers in type B Niemann\u2013Pick disease. J Inherit Metab Dis 28:13\u201320","journal-title":"J Inherit Metab Dis"},{"key":"280_CR19","doi-asserted-by":"crossref","first-page":"6216","DOI":"10.1073\/pnas.082011999","volume":"99","author":"AI Brooks","year":"2002","unstructured":"Brooks AI, Stein CS, Hughes SM, Heth J, McCray PM Jr, Sauter SL, Johnston JC, Cory-Slechta DA, Federoff HJ, Davidson BL (2002) Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc Natl Acad Sci USA 99:6216\u20136221","journal-title":"Proc Natl Acad Sci USA"},{"key":"280_CR20","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","volume":"160","author":"J Charrow","year":"2000","unstructured":"Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ, Zimran A (2000) The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 160:2835\u20132843","journal-title":"Arch Intern Med"},{"key":"280_CR21","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/sj.gene.6363767","volume":"2","author":"EH Choi","year":"2001","unstructured":"Choi EH, Zimmerman PA, Foster CB, Zhu S, Kumaraswami V, Nutman TB, Chanock SJ (2001) Genetic polymorphisms in molecules of innate immunity and susceptibility to infection with Wuchereria bancrofti in South India. Genes Immun 2:248\u2013253","journal-title":"Genes Immun"},{"key":"280_CR22","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ana.20870","volume":"60","author":"C Ciron","year":"2006","unstructured":"Ciron C, Desmaris N, Colle MA, Raoul S, Joussemet B, Verot L, Ausseil J, Froissart R, Roux F, Cherel Y, Ferry N, Lajat Y, Schwartz B, Vanier MT, Maire I, Tardieu M, Moullier P, Heard JM (2006) Gene therapy of the brain in the dog model of Hurler\u2019s syndrome. Ann Neurol 60:204\u2013213","journal-title":"Ann Neurol"},{"key":"280_CR23","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1056\/NEJM199403033300902","volume":"330","author":"CS Cleeland","year":"1994","unstructured":"Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ (1994) Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 330:592\u2013596","journal-title":"N Engl J Med"},{"key":"280_CR24","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","volume":"355","author":"T Cox","year":"2000","unstructured":"Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, Platt F, Butters T, Dwek R, Moyses C, Gow I, Elstein D, Zimran A (2000) Novel oral treatment of Gaucher\u2019s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355:1481\u20131485","journal-title":"Lancet"},{"key":"280_CR25","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1023\/A:1025902113005","volume":"26","author":"TM Cox","year":"2003","unstructured":"Cox TM, Aerts JM, Andria G, Beck M, Belmatoug N, Bembi B, Chertkoff R, Vom Dahl S, Elstein D, Erikson A, Giralt M, Heitner R, Hollak C, Hrebicek M, Lewis S, Mehta A, Pastores GM, Rolfs A, Miranda MC, Zimran A (2003) The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis 26:513\u2013526","journal-title":"J Inherit Metab Dis"},{"key":"280_CR26","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1089\/hum.2004.15.1131","volume":"15","author":"RG Crystal","year":"2004","unstructured":"Crystal RG, Sondhi D, Hackett NR, Kaminsky SM, Worgall S, Stieg P, Souweidane M, Hosain S, Heier L, Ballon D, Dinner M, Wisniewski K, Kaplitt M, Greenwald BM, Howell JD, Strybing K, Dyke J, Voss H (2004) Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. Hum Gene Ther 15:1131\u20131154","journal-title":"Hum Gene Ther"},{"key":"280_CR27","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2004-03-0798","volume":"105","author":"M De Palma","year":"2005","unstructured":"De Palma M, Montini E, de Sio FR, Benedicenti F, Gentile A, Medico E, Naldini L (2005) Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood 105:2307\u20132315","journal-title":"Blood"},{"key":"280_CR28","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ana.20150","volume":"56","author":"N Desmaris","year":"2004","unstructured":"Desmaris N, Verot L, Puech JP, Caillaud C, Vanier MT, Heard JM (2004) Prevention of neuropathology in the mouse model of Hurler syndrome. Ann Neurol 56:68\u201376","journal-title":"Ann Neurol"},{"key":"280_CR29","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1074\/jbc.M309465200","volume":"279","author":"R Dhami","year":"2004","unstructured":"Dhami R, Schuchman EH (2004) Mannose 6-phosphate receptor-mediated uptake is defective in acid sphingomyelinase-deficient macrophages: implications for Niemann\u2013Pick disease enzyme replacement therapy. J Biol Chem 279:1526\u20131532","journal-title":"J Biol Chem"},{"key":"280_CR30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/hum.2005.16.81","volume":"16","author":"C Di Domenico","year":"2005","unstructured":"Di Domenico C, Villani GR, Di Napoli D, Reyero EG, Lombardo A, Naldini L, Di Natale P (2005) Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector. Hum Gene Ther 16:81\u201390","journal-title":"Hum Gene Ther"},{"key":"280_CR31","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:BOLI.0000045756.54006.17","volume":"27","author":"D Elstein","year":"2004","unstructured":"Elstein D, Hollak C, Aerts JM, van Weely S, Maas M, Cox TM, Lachmann RH, Hrebicek M, Platt FM, Butters TD, Dwek RA, Zimran A (2004) Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis 27:757\u2013766","journal-title":"J Inherit Metab Dis"},{"key":"280_CR32","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","volume":"68","author":"CM Eng","year":"2001a","unstructured":"Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, Gass A, Winston J, Dikman S, Fallon JT, Brodie S, Stacy CB, Mehta D, Parsons R, Norton K, O\u2019Callaghan M, Desnick RJ (2001a) A phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68:711\u2013722","journal-title":"Am J Hum Genet"},{"key":"280_CR33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001b","unstructured":"Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ (2001b) Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry\u2019s disease. N Engl J Med 345:9\u201316","journal-title":"N Engl J Med"},{"key":"280_CR34","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1055\/s-2007-979754","volume":"26","author":"A Erikson","year":"1995","unstructured":"Erikson A, Astrom M, Mansson JE (1995) Enzyme infusion therapy of the Norrbottnian (type 3) Gaucher disease. Neuropediatrics 26:203\u2013207","journal-title":"Neuropediatrics"},{"key":"280_CR35","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa042604","volume":"352","author":"ML Escolar","year":"2005","unstructured":"Escolar ML, Poe MD, Provenzale JM, Richards KC, Allison J, Wood S, Wenger DA, Pietryga D, Wall D, Champagne M, Morse R, Krivit W, Kurtzberg J (2005) Transplantation of umbilical-cord blood in babies with infantile Krabbe\u2019s disease. N Engl J Med 352:2069\u20132081","journal-title":"N Engl J Med"},{"key":"280_CR36","first-page":"139","volume":"7","author":"MA Fischl","year":"1994","unstructured":"Fischl MA, Resnick L, Coombs R, Kremer AB, Pottage JC Jr, Fass RJ, Fife KH, Powderly WG, Collier AC, Aspinall RL et al (1994) The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells\/mm3. J Acquir Immune Defic Syndr 7:139\u2013147","journal-title":"J Acquir Immune Defic Syndr"},{"key":"280_CR37","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1182\/blood-2003-09-3217","volume":"103","author":"A Follenzi","year":"2004","unstructured":"Follenzi A, Battaglia M, Lombardo A, Annoni A, Roncarolo MG, Naldini L (2004) Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood 103:3700\u20133709","journal-title":"Blood"},{"key":"280_CR38","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1126\/science.162.3853.570","volume":"162","author":"JC Fratantoni","year":"1968","unstructured":"Fratantoni JC, Hall CW, Neufeld EF (1968) Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science 162:570\u2013572","journal-title":"Science"},{"key":"280_CR39","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1517\/13543784.11.10.1467","volume":"11","author":"DP Germain","year":"2002","unstructured":"Germain DP (2002) Fabry disease: recent advances in enzyme replacement therapy. Expert Opin Investig Drugs 11:1467\u20131476","journal-title":"Expert Opin Investig Drugs"},{"key":"280_CR40","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nrm1050","volume":"4","author":"P Ghosh","year":"2003","unstructured":"Ghosh P, Dahms NM, Kornfeld S (2003) Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol 4:202\u2013212","journal-title":"Nat Rev Mol Cell Biol"},{"key":"280_CR41","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/0309-1651(91)90088-Z","volume":"15","author":"LA Ginsel","year":"1991","unstructured":"Ginsel LA, Fransen JA (1991) Mannose 6-phosphate receptor independent targeting of lysosomal enzymes (a mini-review). Cell Biol Int Rep 15:1167\u20131173","journal-title":"Cell Biol Int Rep"},{"key":"280_CR42","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.semcdb.2004.03.003","volume":"15","author":"L Ginzburg","year":"2004","unstructured":"Ginzburg L, Kacher Y, Futerman AH (2004) The pathogenesis of glycosphingolipid storage disorders. Semin Cell Dev Biol 15:417\u2013431","journal-title":"Semin Cell Dev Biol"},{"key":"280_CR43","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1067\/S0022-3476(03)00302-0","volume":"143","author":"O Goker-Alpan","year":"2003","unstructured":"Goker-Alpan O, Schiffmann R, Park JK, Stubblefield BK, Tayebi N, Sidransky E (2003) Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3. J Pediatr 143:273\u2013276","journal-title":"J Pediatr"},{"key":"280_CR44","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/01.mop.0000172702.33128.19","volume":"17","author":"GA Grabowski","year":"2005","unstructured":"Grabowski GA (2005) Recent clinical progress in Gaucher disease. Curr Opin Pediatr 17:519\u2013524","journal-title":"Curr Opin Pediatr"},{"key":"280_CR45","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","volume":"122","author":"GA Grabowski","year":"1995","unstructured":"Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, Parker C, Schiffmann R, Hill SC, Brady RO (1995) Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 122:33\u201339","journal-title":"Ann Intern Med"},{"key":"280_CR46","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0268-960X(98)90023-6","volume":"12","author":"GA Grabowski","year":"1998","unstructured":"Grabowski GA, Leslie N, Wenstrup R (1998) Enzyme therapy for Gaucher disease: the first 5\u00a0years. Blood Rev 12:115\u2013133","journal-title":"Blood Rev"},{"key":"280_CR47","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/0-387-28957-7_6","volume-title":"Lysosomes","author":"OK Greiner-Tollersrud","year":"2005","unstructured":"Greiner-Tollersrud OK, Berg T (2005) Lysosomal storage disorders. In: Saftig P (ed) Lysosomes, 1st edn. Landes Bioscience, Georgetown, pp 60\u201373","edition":"1"},{"key":"280_CR48","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJM200301163480314","volume":"348","author":"S Hacein-Bey-Abina","year":"2003","unstructured":"Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A (2003) A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348:255\u2013256","journal-title":"N Engl J Med"},{"key":"280_CR49","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1089\/hum.2005.16.1484","volume":"16","author":"NR Hackett","year":"2005","unstructured":"Hackett NR, Redmond DE, Sondhi D, Giannaris EL, Vassallo E, Stratton J, Qiu J, Kaminsky SM, Lesser ML, Fisch GS, Rouselle SD, Crystal RG (2005) Safety of direct administration of AAV2(CU)hCLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to the brain of rats and nonhuman primates. Hum Gene Ther 16:1484\u20131503","journal-title":"Hum Gene Ther"},{"key":"280_CR50","unstructured":"Harmatz P, Giugliani R, Schwartz I, Guffon N, Sa Miranda MC, Teles EL, Wraith E, Beck M, Hopwood J, Swiedler SJ (2004a) A phase 3, randomized, double-blind, placebo-controlled, multicenter, multinational clinical study of recombinant human N-acetylgalactosamine 4-sulfatase (rhASB) in patients with Mucopolysaccharidosis VI (MPS VI) (abstract). The American Society of Human Genetics, Toronto, pp 71"},{"key":"280_CR51","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jpeds.2004.03.018","volume":"144","author":"P Harmatz","year":"2004b","unstructured":"Harmatz P, Whitley CB, Waber L, Pais R, Steiner R, Plecko B, Kaplan P, Simon J, Butensky E, Hopwood JJ (2004b) Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux\u2013Lamy syndrome). J Pediatr 144:574\u2013580","journal-title":"J Pediatr"},{"key":"280_CR52","doi-asserted-by":"crossref","first-page":"e681","DOI":"10.1542\/peds.2004-1023","volume":"115","author":"P Harmatz","year":"2005","unstructured":"Harmatz P, Ketteridge D, Giugliani R, Guffon N, Teles EL, Miranda MC, Yu ZF, Swiedler SJ, Hopwood JJ (2005) Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux\u2013Lamy syndrome): results after 48\u00a0weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 115:e681\u2013e689","journal-title":"Pediatrics"},{"key":"280_CR53","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/bcmd.2002.0497","volume":"28","author":"R Heitner","year":"2002","unstructured":"Heitner R, Elstein D, Aerts J, Weely S, Zimran A (2002) Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol Dis 28:127\u2013133","journal-title":"Blood Cells Mol Dis"},{"key":"280_CR54","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1172\/JCI117084","volume":"93","author":"CE Hollak","year":"1994","unstructured":"Hollak CE, van Weely S, van Oers MH, Aerts JM (1994) Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 93:1288\u20131292","journal-title":"J Clin Invest"},{"key":"280_CR55","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/bcmd.1997.0137","volume":"23","author":"CE Hollak","year":"1997","unstructured":"Hollak CE, Evers L, Aerts JM, van Oers MH (1997) Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis 23:201\u2013212","journal-title":"Blood Cells Mol Dis"},{"key":"280_CR56","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","volume":"112","author":"HM van den Hout","year":"2003","unstructured":"van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, Bakker HD, Loonen MC, de Klerk JB, Reuser AJ, van der Ploeg AT (2003) The natural course of infantile Pompe\u2019s disease: 20 original cases compared with 133 cases from the literature. Pediatrics 112:332\u2013340","journal-title":"Pediatrics"},{"key":"280_CR57","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1046\/j.1538-7836.2003.00305.x","volume":"1","author":"JA Huntington","year":"2003","unstructured":"Huntington JA (2003) Mechanisms of glycosaminoglycan activation of the serpins in hemostasis. J Thromb Haemost 1:1535\u20131549","journal-title":"J Thromb Haemost"},{"key":"280_CR58","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1023\/A:1021259403196","volume":"25","author":"J Imrie","year":"2002","unstructured":"Imrie J, Vijayaraghaven S, Whitehouse C, Harris S, Heptinstall L, Church H, Cooper A, Besley GT, Wraith JE (2002) Niemann\u2013Pick disease type C in adults. J Inherit Metab Dis 25:491\u2013500","journal-title":"J Inherit Metab Dis"},{"key":"280_CR59","doi-asserted-by":"crossref","first-page":"6388","DOI":"10.1073\/pnas.96.11.6388","volume":"96","author":"M Jeyakumar","year":"1999","unstructured":"Jeyakumar M, Butters TD, Cortina-Borja M, Hunnam V, Proia RL, Perry VH, Dwek RA, Platt FM (1999) Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci USA 96:6388\u20136393","journal-title":"Proc Natl Acad Sci USA"},{"key":"280_CR60","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/brain\/awg089","volume":"126","author":"M Jeyakumar","year":"2003","unstructured":"Jeyakumar M, Thomas R, Elliot-Smith E, Smith DA, van der Spoel AC, d\u2019Azzo A, Perry VH, Butters TD, Dwek RA, Platt FM (2003) Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain 126:974\u2013987","journal-title":"Brain"},{"key":"280_CR61","first-page":"120","volume-title":"Enzyme therapy in genetic diseases","author":"WG Johnson","year":"1973","unstructured":"Johnson WG, Desnick RJ, Long DM, Sharp M, Krivit W, Brady R (1973) Intravenous injection of purified hexosaminidase A into patients with Tay\u2013Sachs disease. In: Desnick RJ, Bernlohr R, Krivit W (eds) Enzyme therapy in genetic diseases. Alan R. Liss, New York, pp 120"},{"key":"280_CR62","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/S0140-6736(03)13311-9","volume":"361","author":"R Kakavanos","year":"2003","unstructured":"Kakavanos R, Turner CT, Hopwood JJ, Kakkis ED, Brooks DA (2003) Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I. Lancet 361:1608\u20131613","journal-title":"Lancet"},{"key":"280_CR63","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM200101183440304","volume":"344","author":"ED Kakkis","year":"2001","unstructured":"Kakkis ED, Muenzer J, Tiller GE, Waber L, John Belmont J, Merry Passage M, Izykowski B, Phillips J, Doroshow R, Irv Walot I, Richard Hoft R, Yu KT, Okazaki S, Dave Lewis D, Ralph Lachman R, Jerry N, Thompson JN, Neufeld FE (2001) Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 344:182\u2013188","journal-title":"N Engl J Med"},{"key":"280_CR64","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1750-3639.2006.00002.x","volume":"16","author":"GW Kay","year":"2006","unstructured":"Kay GW, Palmer DN, Rezaie P, Cooper JD (2006) Activation of non-neuronal cells within the prenatal developing brain of sheep with neuronal ceroid lipofuscinosis. Brain Pathol 16:110\u2013116","journal-title":"Brain Pathol"},{"key":"280_CR65","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.jpeds.2004.01.053","volume":"144","author":"PS Kishnani","year":"2004","unstructured":"Kishnani PS, Howell RR (2004) Pompe disease in infants and children. J Pediatr 144:S35\u2013S43","journal-title":"J Pediatr"},{"key":"280_CR66","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ymgme.2005.01.007","volume":"85","author":"T Kitagawa","year":"2005","unstructured":"Kitagawa T, Ishige N, Suzuki K, Owada M, Ohashi T, Kobayashi M, Eto Y, Tanaka A, Mills K, Winchester B, Keutzer J (2005) Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry. Mol Genet Metab 85:196\u2013202","journal-title":"Mol Genet Metab"},{"key":"280_CR67","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1146\/annurev.cb.05.110189.002411","volume":"5","author":"S Kornfeld","year":"1989","unstructured":"Kornfeld S, Mellman I (1989) The biogenesis of lysosomes. Annu Rev Cell Biol 5:483\u2013525","journal-title":"Annu Rev Cell Biol"},{"key":"280_CR68","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00019052-199904000-00007","volume":"12","author":"W Krivit","year":"1999","unstructured":"Krivit W, Peters C, Shapiro EG (1999) Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux\u2013Lamy, and Sly syndromes, and Gaucher disease type III. Curr Opin Neurol 12:167\u2013176","journal-title":"Curr Opin Neurol"},{"key":"280_CR69","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.nbd.2004.05.002","volume":"16","author":"RH Lachmann","year":"2004","unstructured":"Lachmann RH, Te Vruchte D, Lloyd-Evans E, Reinkensmeier G, Sillence DJ, Fernandez-Guillen L, Dwek RA, Butters TD, Cox TM, Platt FM (2004) Treatment with miglustat reverses the lipid-trafficking defect in Niemann\u2013Pick disease type C. Neurobiol Dis 16:654\u2013658","journal-title":"Neurobiol Dis"},{"key":"280_CR70","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/glycob\/cwg034","volume":"13","author":"K Lee","year":"2003","unstructured":"Lee K, Jin X, Zhang K, Copertino L, Andrews L, Baker-Malcolm J, Geagan L, Qiu H, Seiger K, Barngrover D, McPherson JM, Edmunds T (2003) A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 13:305\u2013313","journal-title":"Glycobiology"},{"key":"280_CR71","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1006\/mthe.2002.0605","volume":"5","author":"C Li","year":"2002","unstructured":"Li C, Ziegler RJ, Cherry M, Lukason M, Desnick RJ, Yew NS, Cheng SH (2002) Adenovirus-transduced lung as a portal for delivering alpha-galactosidase a into systemic circulation for Fabry disease. Mol Ther 5:745\u2013754","journal-title":"Mol Ther"},{"key":"280_CR72","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","volume":"66","author":"GE Linthorst","year":"2004","unstructured":"Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM (2004) Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 66:1589\u20131595","journal-title":"Kidney Int"},{"key":"280_CR73","first-page":"1003","volume":"17","author":"G Malm","year":"1996","unstructured":"Malm G, Ringden O, Winiarski J, Grondahl E, Uyebrant P, Eriksson U, Hakansson H, Skjeldal O, Mansson JE (1996) Clinical outcome in four children with metachromatic leukodystrophy treated by bone marrow transplantation. Bone Marrow Transplant 17:1003\u20131008","journal-title":"Bone Marrow Transplant"},{"key":"280_CR74","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2004.01.015","volume":"82","author":"RL Mango","year":"2004","unstructured":"Mango RL, Xu L, Sands MS, Vogler C, Seiler G, Schwarz T, Haskins ME, Ponder KP (2004) Neonatal retroviral vector-mediated hepatic gene therapy reduces bone, joint, and cartilage disease in mucopolysaccharidosis VII mice and dogs. Mol Genet Metab 82:4\u201319","journal-title":"Mol Genet Metab"},{"key":"280_CR75","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1006\/bcmd.2002.0547","volume":"29","author":"M Masoud","year":"2002","unstructured":"Masoud M, Rudensky B, Elstein D, Zimran A (2002) Chitotriosidase deficiency in survivors of Candida sepsis. Blood Cells Mol Dis 29:116\u2013118","journal-title":"Blood Cells Mol Dis"},{"key":"280_CR76","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1517\/14712598.5.1.55","volume":"5","author":"U Matzner","year":"2005","unstructured":"Matzner U, Gieselmann V (2005) Gene therapy of metachromatic leukodystrophy. Expert Opin Biol Ther 5:55\u201365","journal-title":"Expert Opin Biol Ther"},{"key":"280_CR77","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","volume":"34","author":"A Mehta","year":"2004","unstructured":"Mehta A, Ricci R, Widmer U, Dehout F, De Garcia Lorenzo A, Kampmann C, Linhart A, Sunder-Plassmann G, Ries M, Beck M (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry outcome survey. Eur J Clin Invest 34:236\u2013242","journal-title":"Eur J Clin Invest"},{"key":"280_CR78","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ymgme.2006.02.013","volume":"88","author":"PJ Meikle","year":"2006","unstructured":"Meikle PJ, Grasby DJ, Dean CJ, Lang DL, Bockmann M, Whittle AM, Fietz MJ, Simonsen H, Fuller M, Brooks DA, Hopwood JJ (2006) Newborn screening for lysosomal storage disorders. Mol Genet Metab 88:307\u2013314","journal-title":"Mol Genet Metab"},{"key":"280_CR79","first-page":"595","volume":"163","author":"K Mills","year":"2004","unstructured":"Mills K, Vellodi A, Morris P, Cooper D, Morris M, Young E, Winchester B (2004) Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease. Eur J Pediatr 163:595\u2013603","journal-title":"Eur J Pediatr"},{"key":"280_CR80","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.0902-4441.2003.00193.x","volume":"72","author":"HJ Moller","year":"2004","unstructured":"Moller HJ, Fost Md, Aerts H, Hollak C, Moestrup SK (2004) Plasma level of the macrophage-derived soluble CD163 is increased and positively correlates with severity in Gaucher\u2019s disease. Eur J Haematol 72:135\u2013139","journal-title":"Eur J Haematol"},{"key":"280_CR81","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.jpeds.2004.01.052","volume":"144","author":"J Muenzer","year":"2004","unstructured":"Muenzer J (2004) The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. J Pediatr 144:S27\u2013S34","journal-title":"J Pediatr"},{"issue":"Suppl","key":"280_CR82","first-page":"582","volume":"71","author":"J Muenzer","year":"2002","unstructured":"Muenzer J, Towle D, Calikoglu M, McCandllles S (2002) A phase I\/II clinical study evaluating the safety and clinical activity of enzyme replacement therapy in Mucopolysaccharidosis II (Hunter syndrome). Am J Hum Genet 71(Suppl):582","journal-title":"Am J Hum Genet"},{"key":"280_CR83","unstructured":"Muenzer J, Wraight EP, Beck M, Giugliani R, Harmatz P, Eng CM, Vellodi A, Martin R, Ramaswami U, Calikoglu M, Vijayaraghavan S, Puga A, Ulbrich B, Shinawi M, Cleary M, Wendt S (2005) The phase II\/III I2S enzyme replacement (ERT) clinical trial results for MPS II. 55th Annual Meeting American Society of Human Genetics, Salt Lake City, Utah"},{"key":"280_CR84","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","volume":"8","author":"J Muenzer","year":"2006","unstructured":"Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, Vellodi A, Martin R, Ramaswami U, Gucsavas-Calikoglu M, Vijayaraghavan S, Wendt S, Puga A, Ulbrich B, Shinawi M, Cleary M, Piper D, Conway AM, Kimura A (2006) A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 8:465\u2013473","journal-title":"Genet Med"},{"key":"280_CR85","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1073\/pnas.252784899","volume":"100","author":"K Ohmi","year":"2003","unstructured":"Ohmi K, Greenberg DS, Rajavel KS, Ryazantsev S, Li HH, Neufeld EF (2003) Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc Natl Acad Sci USA 100:1902\u20131907","journal-title":"Proc Natl Acad Sci USA"},{"key":"280_CR86","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ymthe.2005.02.031","volume":"12","author":"KO Orii","year":"2005","unstructured":"Orii KO, Grubb JH, Vogler C, Levy B, Tan Y, Markova K, Davidson BL, Mao Q, Orii T, Kondo N, Sly WS (2005) Defining the pathway for Tat-mediated delivery of beta-glucuronidase in cultured cells and MPS VII mice. Mol Ther 12:345\u2013352","journal-title":"Mol Ther"},{"key":"280_CR87","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1203\/00006450-200008000-00018","volume":"48","author":"E Orvisky","year":"2000","unstructured":"Orvisky E, Sidransky E, McKinney CE, Lamarca ME, Samimi R, Krasnewich D, Martin BM, Ginns EI (2000) Glucosylsphingosine accumulation in mice and patients with type 2 Gaucher disease begins early in gestation. Pediatr Res 48:233\u2013237","journal-title":"Pediatr Res"},{"key":"280_CR88","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1523\/JNEUROSCI.2676-05.2006","volume":"26","author":"MA Passini","year":"2006","unstructured":"Passini MA, Dodge JC, Bu J, Yang W, Zhao Q, Sondhi D, Hackett NR, Kaminsky SM, Mao Q, Shihabuddin LS, Cheng SH, Sleat DE, Stewart GR, Davidson BL, Lobel P, Crystal RG (2006) Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis. J Neurosci 26:1334\u20131342","journal-title":"J Neurosci"},{"key":"280_CR89","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1517\/13543784.12.2.273","volume":"12","author":"GM Pastores","year":"2003","unstructured":"Pastores GM, Barnett NL (2003) Substrate reduction therapy: miglustat as a remedy for symptomatic patients with Gaucher disease type 1. Expert Opin Investig Drugs 12:273\u2013281","journal-title":"Expert Opin Investig Drugs"},{"key":"280_CR90","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1023\/A:1005622001239","volume":"23","author":"D Pelled","year":"2000","unstructured":"Pelled D, Shogomori H, Futerman AH (2000) The increased sensitivity of neurons with elevated glucocerebroside to neurotoxic agents can be reversed by imiglucerase. J Inherit Metab Dis 23:175\u2013184","journal-title":"J Inherit Metab Dis"},{"key":"280_CR91","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/sj.bmt.1703839","volume":"31","author":"C Peters","year":"2003","unstructured":"Peters C, Steward CG (2003) Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant 31:229\u2013239","journal-title":"Bone Marrow Transplant"},{"key":"280_CR92","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s002560100375","volume":"30","author":"LW Poll","year":"2001","unstructured":"Poll LW, Koch JA, vom Dahl S, Willers R, Scherer A, Boerner D, Niederau C, Haussinger D, Modder U (2001) Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results. Skeletal Radiol 30:496\u2013503","journal-title":"Skeletal Radiol"},{"key":"280_CR93","doi-asserted-by":"crossref","first-page":"A25","DOI":"10.1259\/bjr.75.suppl_1.750025","volume":"75","author":"LW Poll","year":"2002","unstructured":"Poll LW, Maas M, Terk MR, Roca-Espiau M, Bembi B, Ciana G, Weinreb NJ (2002) Response of Gaucher bone disease to enzyme replacement therapy. Br J Radiol 75:A25\u2013A36","journal-title":"Br J Radiol"},{"key":"280_CR94","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/(SICI)1096-8628(19970711)71:1<16::AID-AJMG3>3.0.CO;2-O","volume":"71","author":"CA Prows","year":"1997","unstructured":"Prows CA, Sanchez N, Daugherty C, Grabowski GA (1997) Gaucher disease: enzyme therapy in the acute neuronopathic variant. Am J Med Genet 71:16\u201321","journal-title":"Am J Med Genet"},{"key":"280_CR95","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ymgme.2003.08.022","volume":"80","author":"N Raben","year":"2003","unstructured":"Raben N, Danon M, Gilbert AL, Dwivedi S, Collins B, Thurberg BL, Mattaliano RJ, Nagaraju K, Plotz PH (2003) Enzyme replacement therapy in the mouse model of Pompe disease. Mol Genet Metab 80:159\u2013169","journal-title":"Mol Genet Metab"},{"key":"280_CR96","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF00731489","volume":"13","author":"NS Radin","year":"1996","unstructured":"Radin NS (1996) Treatment of Gaucher disease with an enzyme inhibitor. Glycoconj J 13:153\u2013157","journal-title":"Glycoconj J"},{"key":"280_CR97","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ymgme.2006.01.005","volume":"88","author":"DR Randall","year":"2006","unstructured":"Randall DR, Sinclair GB, Colobong KE, Hetty E, Clarke LA (2006) Heparin cofactor II\u2013thrombin complex in MPS I: a biomarker of MPS disease. Mol Genet Metab 88:235\u2013243","journal-title":"Mol Genet Metab"},{"key":"280_CR98","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1182\/blood.V93.6.2081.406k07_2081_2088","volume":"93","author":"M Rosenberg","year":"1999","unstructured":"Rosenberg M, Kingma W, Fitzpatrick MA, Richards SM (1999) Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood 93:2081\u20132088","journal-title":"Blood"},{"key":"280_CR99","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ymthe.2006.01.006","volume":"13","author":"MS Sands","year":"2006","unstructured":"Sands MS, Davidson BL (2006) Gene therapy for lysosomal storage diseases. Mol Ther 13:839\u2013849","journal-title":"Mol Ther"},{"key":"280_CR100","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ymgme.2004.05.005","volume":"82","author":"PS Savas","year":"2004","unstructured":"Savas PS, Hemsley KM, Hopwood JJ (2004) Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA. Mol Genet Metab 82:273\u2013285","journal-title":"Mol Genet Metab"},{"key":"280_CR101","doi-asserted-by":"crossref","first-page":"15428","DOI":"10.1073\/pnas.192582899","volume":"99","author":"AR Sawkar","year":"2002","unstructured":"Sawkar AR, Cheng WC, Beutler E, Wong CH, Balch WE, Kelly JW (2002) Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci USA 99:15428\u201315433","journal-title":"Proc Natl Acad Sci USA"},{"key":"280_CR102","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ana.410420412","volume":"42","author":"R Schiffmann","year":"1997","unstructured":"Schiffmann R, Heyes MP, Aerts JM, Dambrosia JM, Patterson MC, DeGraba T, Parker CC, Zirzow GC, Oliver K, Tedeschi G, Brady RO, Barton NW (1997) Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher\u2019s disease. Ann Neurol 42:613\u2013621","journal-title":"Ann Neurol"},{"key":"280_CR103","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA III, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285:2743\u20132749","journal-title":"JAMA"},{"key":"280_CR104","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1203\/01.PDR.0000156510.96253.5A","volume":"57","author":"CM Simonaro","year":"2005","unstructured":"Simonaro CM, D\u2019Angelo M, Haskins ME, Schuchman EH (2005) Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr Res 57:701\u2013707","journal-title":"Pediatr Res"},{"key":"280_CR105","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/sj.gt.3302549","volume":"12","author":"D Sondhi","year":"2005","unstructured":"Sondhi D, Peterson DA, Giannaris EL, Sanders CT, Mendez BS, De B, Rostkowski AB, Blanchard B, Bjugstad K, Sladek JR Jr, Redmond DE Jr, Leopold PL, Kaminsky SM, Hackett NR, Crystal RG (2005) AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL. Gene Ther 12:1618\u20131632","journal-title":"Gene Ther"},{"key":"280_CR106","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1056\/NEJMoa032613","volume":"350","author":"SL Staba","year":"2004","unstructured":"Staba SL, Escolar ML, Poe M, Kim Y, Martin PL, Szabolcs P, Allison-Thacker J, Wood S, Wenger DA, Rubinstein P, Hopwood JJ, Krivit W, Kurtzberg J (2004) Cord-blood transplants from unrelated donors in patients with Hurler\u2019s syndrome. N Engl J Med 350:1960\u20131969","journal-title":"N Engl J Med"},{"key":"280_CR107","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajmg.a.30579","volume":"134A","author":"SJ Swiedler","year":"2005","unstructured":"Swiedler SJ, Beck M, Bajbouj M, Giugliani R, Schwartz I, Harmatz P, Wraith JE, Roberts J, Ketteridge D, Hopwood JJ, Guffon N, Sa Miranda MC, Teles EL, Berger KI, Piscia-Nichols C (2005) Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux\u2013Lamy syndrome). Am J Med Genet A 134A:144\u2013150","journal-title":"Am J Med Genet A"},{"key":"280_CR108","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/00042560-199510050-00008","volume":"10","author":"M Tierney","year":"1995","unstructured":"Tierney M, Pottage J, Kessler H, Fischl M, Richman D, Merigan T, Powderly W, Smith S, Karim A, Sherman J et al (1995) The tolerability and pharmacokinetics of N-butyl-deoxynojirimycin in patients with advanced HIV disease (ACTG 100). The AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and Infectious Diseases. J Acquir Immune Defic Syndr Hum Retrovirol 10:549\u2013553","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"280_CR109","doi-asserted-by":"crossref","first-page":"13478","DOI":"10.1074\/jbc.M308523200","volume":"279","author":"MB Tropak","year":"2004","unstructured":"Tropak MB, Reid SP, Guiral M, Withers SG, Mahuran D (2004) Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay\u2013Sachs and Sandhoff Patients. J Biol Chem 279:13478\u201313487","journal-title":"J Biol Chem"},{"key":"280_CR110","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1542\/peds.113.5.e448","volume":"113","author":"JM Van den Hout","year":"2004","unstructured":"Van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, De Klerk JB, Loonen MC, Vulto AG, Cromme-Dijkhuis A, Weisglas-Kuperus N, Hop W, Van Hirtum H, Van Diggelen OP, Boer M, Kroos MA, Van Doorn PA, Van der Voort E, Sibbles B, Van Corven EJ, Brakenhoff JP, Van Hove J, Smeitink JA, de Jong G, Reuser AJ, Van der Ploeg AT (2004) Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113:e448\u2013e457","journal-title":"Pediatrics"},{"key":"280_CR111","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1172\/JCI115025","volume":"87","author":"AT Van der Ploeg","year":"1991","unstructured":"Van der Ploeg AT, Kroos MA, Willemsen R, Brons NH, Reuser AJ (1991) Intravenous administration of phosphorylated acid alpha-glucosidase leads to uptake of enzyme in heart and skeletal muscle of mice. J Clin Invest 87:513\u2013518","journal-title":"J Clin Invest"},{"key":"280_CR112","doi-asserted-by":"crossref","first-page":"10954","DOI":"10.1073\/pnas.97.20.10954","volume":"97","author":"R Wada","year":"2000","unstructured":"Wada R, Tifft CJ, Proia RL (2000) Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc Natl Acad Sci USA 97:10954\u201310959","journal-title":"Proc Natl Acad Sci USA"},{"key":"280_CR113","doi-asserted-by":"crossref","first-page":"e672","DOI":"10.1542\/peds.2004-0887","volume":"114","author":"MP Wasserstein","year":"2004","unstructured":"Wasserstein MP, Desnick RJ, Schuchman EH, Hossain S, Wallenstein S, Lamm C, McGovern MM (2004) The natural history of type B Niemann\u2013Pick disease: results from a 10-year longitudinal study. Pediatrics 114:e672\u2013e677","journal-title":"Pediatrics"},{"key":"280_CR114","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","volume":"108","author":"F Weidemann","year":"2003","unstructured":"Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W, Ertl G, Knoll A, Wanner C, Strotmann JM (2003) Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 108:1299\u20131301","journal-title":"Circulation"},{"key":"280_CR115","first-page":"723","volume":"23","author":"J Wenk","year":"1991","unstructured":"Wenk J, Hille A, von Figura K (1991) Quantitation of Mr 46000 and Mr 300000 mannose 6-phosphate receptors in human cells and tissues. Biochem Int 23:723\u2013731","journal-title":"Biochem Int"},{"key":"280_CR116","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","volume":"75","author":"WR Wilcox","year":"2004","unstructured":"Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75:65\u201374","journal-title":"Am J Hum Genet"},{"issue":"Suppl A","key":"280_CR117","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/ejpn.2000.0428","volume":"5","author":"BG Winchester","year":"2001","unstructured":"Winchester BG (2001) Lysosomal membrane proteins. Eur J Paediatr Neurol 5(Suppl A):11\u201319","journal-title":"Eur J Paediatr Neurol"},{"key":"280_CR118","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","volume":"144","author":"JE Wraith","year":"2004","unstructured":"Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, Rapoport DM, Berger KI, Swiedler SJ, Kakkis ED, Braakman T, Chadbourne E, Walton-Bowen K, Cox GF (2004) Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-l-iduronidase (laronidase). J Pediatr 144:581\u2013588","journal-title":"J Pediatr"},{"key":"280_CR119","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/90242","volume":"19","author":"H Xia","year":"2001","unstructured":"Xia H, Mao Q, Davidson BL (2001) The HIV Tat protein transduction domain improves the biodistribution of beta-glucuronidase expressed from recombinant viral vectors. Nat Biotechnol 19:640\u2013644","journal-title":"Nat Biotechnol"},{"key":"280_CR120","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1096\/fj.04-2375com","volume":"19","author":"GH Yam","year":"2005","unstructured":"Yam GH, Zuber C, Roth J (2005) A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder. FASEB J 19:12\u201318","journal-title":"FASEB J"},{"key":"280_CR121","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0960-9822(01)00396-7","volume":"11","author":"M Zervas","year":"2001","unstructured":"Zervas M, Somers KL, Thrall MA, Walkley SU (2001) Critical role for glycosphingolipids in Niemann\u2013Pick disease type C. Curr Biol 11:1283\u20131287","journal-title":"Curr Biol"},{"key":"280_CR122","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1096-7192(03)00116-1","volume":"79","author":"Y Zheng","year":"2003","unstructured":"Zheng Y, Rozengurt N, Ryazantsev S, Kohn DB, Satake N, Neufeld EF (2003) Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow. Mol Genet Metab 79:233\u2013244","journal-title":"Mol Genet Metab"}],"container-title":["Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00439-006-0280-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00439-006-0280-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00439-006-0280-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00439-006-0280-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T02:10:54Z","timestamp":1659060654000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00439-006-0280-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,7]]},"references-count":122,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["280"],"URL":"https:\/\/doi.org\/10.1007\/s00439-006-0280-4","relation":{},"ISSN":["0340-6717","1432-1203"],"issn-type":[{"value":"0340-6717","type":"print"},{"value":"1432-1203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11,7]]},"assertion":[{"value":"22 May 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2006","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}